| Indicators | Browse All

LeonaBio, Inc. (LONA)

Healthcare | Biotechnology | Bothell, United States | NasdaqCM
5.39 USD -1.04 (-16.174%) ⇩ (Oct. 14, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 5:34 a.m. EDT

The immediate outlook is severely clouded by a catastrophic multi-year price collapse. Over the last five years, the stock has lost 97.74% of its value, with every single year showing negative returns. This relentless downward trajectory suggests the market has thoroughly rejected the company's business model, pricing it well below any potential recovery scenario. While the balance sheet currently shows low debt relative to equity, this is likely a result of massive share dilution rather than organic strength, evidenced by the recent awarding of tens of thousands of stock options. The recent price action shows a volatile bounce off lows, but without any sign of stabilizing revenue or profitability, this appears to be a speculative trap rather than a genuine recovery. With no dividend to provide income and fundamentals deteriorating across all metrics, the investment case remains non-existent.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.158023
AutoETS0.158023
MSTL0.159000
AutoTheta0.166220

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 16%
H-stat 21.24
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 3.39
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.718
Market Cap 50,782,764
Beta 2.12
Previous Name Athira Pharma, Inc.
Website https://www.leonabio.com

Info Dump

Attribute Value
52 Week Change 0.7568306
Address1 18,706 North Creek Parkway
Address2 Suite 104
All Time High 347.9
All Time Low 2.2
Ask 4.9
Ask Size 1
Audit Risk 10
Average Analyst Rating 1.5 - Strong Buy
Average Daily Volume10 Day 796,710
Average Daily Volume3 Month 190,309
Average Volume 190,309
Average Volume10Days 796,710
Beta 2.115
Bid 5.64
Bid Size 1
Board Risk 5
Book Value 3.566
City Bothell
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 7
Country United States
Crypto Tradeable 0
Currency USD
Current Price 5.39
Current Ratio 7.011
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 6.33
Day Low 5.25
Debt To Equity 1.718
Display Name LeonaBio
Dividend Yield 0.0
Earnings Timestamp End 1,786,046,400
Earnings Timestamp Start 1,786,046,400
Ebitda -53,828,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.005
Enterprise Value 292,763
Eps Trailing Twelve Months -23.01
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 6.7513
Fifty Day Average Change -1.3613
Fifty Day Average Change Percent -0.20163524
Fifty Two Week Change Percent 75.68306
Fifty Two Week High 14.21
Fifty Two Week High Change -8.82
Fifty Two Week High Change Percent -0.62068963
Fifty Two Week Low 2.21
Fifty Two Week Low Change 3.1799998
Fifty Two Week Low Change Percent 1.438914
Fifty Two Week Range 2.21 - 14.21
Financial Currency USD
First Trade Date Milliseconds 1,600,435,800,000
Float Shares 4,730,429
Free Cashflow -23,139,500
Full Exchange Name NasdaqCM
Full Time Employees 19
Fullday Change -0.9299998
Fullday Change Percent -14.46345
Fullday Price 5.39
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,790,812,800
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.040689997
Held Percent Institutions 0.87661004
Implied Shares Outstanding 9,421,663
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,758,153,600
Last Split Factor 1:10
Long Business Summary LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Long Name LeonaBio, Inc.
Market us_market
Market Cap 50,782,764
Market State PRE
Max Age 86,400
Message Board Id finmb_266015004
Most Recent Quarter 1,782,777,600
Name Change Date 2,026-10-15
Net Income To Common -141,455,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 55,493,595
Number Of Analyst Opinions 3
Open 6.33
Operating Cashflow -61,926,000
Operating Margins 0.0
Overall Risk 8
Phone 425 620 8501
Prev Name Athira Pharma, Inc.
Previous Close 6.43
Price Hint 2
Price To Book 1.5114975
Profit Margins 0.0
Quick Ratio 6.533
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.5
Region US
Regular Market Change -1.04
Regular Market Change Percent -16.174183
Regular Market Day High 6.33
Regular Market Day Low 5.25
Regular Market Day Range 5.25 - 6.33
Regular Market Open 6.33
Regular Market Previous Close 6.43
Regular Market Price 5.39
Regular Market Time 1,792,008,001
Regular Market Volume 103,020
Return On Assets -0.74065
Return On Equity -4.3139
Sand P52 Week Change 0.1570785
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 9,421,663
Shares Percent Shares Out 0.002
Shares Short 19,166
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 40,293
Short Name LeonaBio, Inc.
Short Percent Of Float 0.0026
Short Ratio 0.15
Source Interval 15
State WA
Symbol LONA
Target High Price 20.0
Target Low Price 15.0
Target Mean Price 17.33333
Target Median Price 17.0
Total Cash 51,067,000
Total Cash Per Share 5.42
Total Debt 577,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -23.01
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.634325
Two Hundred Day Average Change -2.2443252
Two Hundred Day Average Change Percent -0.2939782
Type Disp Equity
Volume 103,020
Website https://www.leonabio.com
Zip 98,011